...
首页> 外文期刊>Cancer Cell International >Prognosis of the intrahepatic cholangiocarcinoma after resection: hepatitis B virus infection and adjuvant chemotherapy are favorable prognosis factors
【24h】

Prognosis of the intrahepatic cholangiocarcinoma after resection: hepatitis B virus infection and adjuvant chemotherapy are favorable prognosis factors

机译:肝内胆管癌切除后的预后:乙肝病毒感染和辅助化疗是良好的预后因素

获取原文
           

摘要

The incidence and mortality associated with intrahepatic cholangiocarcinoma is increasing in many countries and documentation of disease outcome is sparse. The present study was undertaken to investigate the prognostic factors for intrahepatic cholangiocarcinoma (ICC) following surgical resection. The impact of pre-existing HBV virus infection and adjuvant chemotherapy on the overall survival was also evaluated. Clinical and pathological data were collected retrospectively from 81 patients undergoing surgery for ICC between 2005 and 2011, at The Henan Province Tumor Hospital and the First Affiliated Hospital of Zheng Zhou University. Survival and prognosis were analyzed using the Kaplan-Meier method and COX regression model. The population included 37 patients who were HBsAg + or anti-HBc+, 21 patients who were anti-HBs + positive and 18 patients who received adjuvant chemotherapy. The overall 1- and 3-year survival rates were 51% and 20%, respectively. The median survival was 12.2 months. Univariate analysis identified the following prognostic factors: HBV virus infection or HBV vaccine prior to resection (P = 0.017); adjuvant chemotherapy (P = 0.001); preoperative serum CA19-9 ( 200 U/mL; P = 0.015); GGT ( 64 U/L; P = 0.008), ALP ( 119 U/L; P = 0.01); lymph node metastasis (P = 0.005); radical resection (P = 0.021); intrahepatic metastasis (P = 0.015) and diabetes (P = 0.07). Multivariate analysis identified chronic HBV infection (RR = 0.583; P = 0.041), anti-HBs positivity (RR = 0.680; P = 0.050), adjuvant chemotherapy (RR = 0.227; P  0.001), lymph node metastasis (RR = 2.320; P = 0.001), and intrahepatic duct stones (RR = 0.473; P = 0.032) as independent prognostic factors. HBV virus infection or HBV vaccination prior to resection, together with adjuvant chemotherapy, were independently associated with improved survival in patients undergoing surgery for ICC.
机译:在许多国家,与肝内胆管癌相关的发病率和死亡率正在增加,并且疾病结局的文献稀少。本研究旨在探讨手术切除后肝内胆管癌(ICC)的预后因素。还评估了预先存在的HBV病毒感染和辅助化疗对总体生存的影响。回顾性收集2005年至2011年在河南省肿瘤医院和郑州大学第一附属医院接受ICC手术的81例患者的临床和病理数据。使用Kaplan-Meier方法和COX回归模型分析生存率和预后。人群包括HBsAg +或抗HBc +的37例患者,抗HBs +阳性的21例和辅助化疗的18例。一年和三年的总生存率分别为51%和20%。中位生存期为12.2个月。单因素分析确定了以下预后因素:切除前的HBV病毒感染或HBV疫苗(P = 0.017);辅助化疗(P = 0.001);术前血清CA19-9(> 200 U / mL; P = 0.015); GGT(> 64 U / L; P = 0.008),ALP(> 119 U / L; P = 0.01);淋巴结转移(P = 0.005);根治性切除(P = 0.021);肝内转移(P = 0.015)和糖尿病(P = 0.07)。多变量分析确定了慢性HBV感染(RR = 0.583; P = 0.041),抗HBs阳性(RR = 0.680; P = 0.050),辅助化疗(RR = 0.227; P <0.001),淋巴结转移(RR = 2.320; P = 0.001)和肝内导管结石(RR = 0.473; P = 0.032)是独立的预后因素。在接受ICC手术的患者中,切除前的HBV病毒感染或HBV疫苗接种以及辅助化疗与生存率的改善独立相关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号